Free Trial
→ Top Trader Reveals Stunning Black Friday Deal (From Base Camp Trading) (Ad)tc pixel Free CNSY Stock Alerts

Plus Therapeutics (CNSY) Financials

Plus Therapeutics logo
$0.95 +0.18 (+23.32%)
Closing price 04:00 PM Eastern
Extended Trading
$0.92 -0.03 (-3.49%)
As of 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Plus Therapeutics

Annual Income Statements for Plus Therapeutics

This table shows Plus Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -19 -22 -27 -15 -11 -8.24 -13 -20 -13 -13 -22
Consolidated Net Income / (Loss)		 -19 -22 -23 -13 -11 -8.24 -13 -20 -13 -13 -22
Net Income / (Loss) Continuing Operations		 -19 -22 -23 -8.88 -3.28 -8.24 -13 -20 -13 -13 -22
Total Pre-Tax Income 		-19 -22 -23 -8.41 -5.46 -8.24 -13 -20 -13 -13 -22
Total Operating Income		 -15 -20 -21 -8.76 -3.66 -9.58 -12 -20 -13 -15 -15
Total Gross Profit		 1.65 1.94 0.15 0.00 0.00 0.00 0.00 0.22 4.91 5.82 5.21
Total Revenue		 4.84 4.66 2.69 0.00 0.00 0.00 0.00 0.22 4.91 5.82 5.21
Operating Revenue		 4.84 4.66 2.69 - - - 0.00 0.22 4.91 5.82 5.21
Total Cost of Revenue		 3.19 2.72 2.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 17 22 21 8.76 3.66 9.58 12 20 18 21 21
Selling, General & Admin Expense		 9.77 8.56 7.59 5.58 5.29 6.41 6.85 10 8.54 9.94 12
Research & Development Expense		 12 9.47 13 5.52 5.37 3.48 5.57 9.70 9.69 11 8.38
Total Other Income / (Expense), net		 -3.46 -2.34 -2.00 0.35 -1.80 1.34 -0.91 -0.56 0.01 1.72 -7.09
Interest Expense		 3.64 2.59 2.05 1.92 1.86 1.11 0.93 0.71 0.40 0.18 0.55
Interest & Investment Income		 0.01 0.02 0.03 0.04 0.06 0.05 0.02 0.15 0.40 0.27 0.12
Other Income / (Expense), net		 0.17 0.23 0.01 2.23 - 2.40 0.01 - 0.00 1.62 -6.66
Basic Earnings per Share		 ($2.07) ($1.28) ($8.23) ($86.98) ($8.27) ($1.86) ($1.11) ($11.58) ($4.24) ($1.95) ($0.29)
Weighted Average Basic Shares Outstanding		 9.39M 17.29M 3.24M 173.85K 1.38M 4.43M 12.09M 1.75M 3.14M 6.64M 77.80M
Diluted Earnings per Share		 ($2.07) ($1.28) ($8.23) ($86.98) ($8.27) ($1.86) ($1.11) ($11.58) ($4.24) ($2.34) ($0.29)
Weighted Average Diluted Shares Outstanding		 9.39M 17.29M 3.24M 173.85K 1.38M 4.43M 12.09M 1.75M 3.14M 7.70M 77.80M
Weighted Average Basic & Diluted Shares Outstanding		 9.39M 17.29M 3.24M 173.85K 1.38M 4.43M 12.09M 35.11M 4.28M 17.00M 171.55M

Quarterly Income Statements for Plus Therapeutics

This table shows Plus Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -3.81 -3.26 -2.94 -2.87 -3.90 -17 5.15 -4.42 -5.71 -6.95 -9.01
Consolidated Net Income / (Loss)		 -3.81 -3.26 -2.94 -2.87 -3.90 -17 5.15 -4.42 -5.71 -6.95 -9.01
Net Income / (Loss) Continuing Operations		 -3.85 -3.26 -2.94 -2.87 -3.90 -17 5.15 -4.42 -5.71 -6.95 -8.96
Total Pre-Tax Income 		-3.81 -3.26 -2.94 -2.87 -3.90 -17 5.15 -4.42 -5.71 -6.95 -9.01
Total Operating Income		 -3.86 -3.30 -3.70 -3.80 -3.90 -3.54 -1.54 -4.48 -5.74 -7.12 -9.06
Total Gross Profit		 1.31 1.68 1.28 1.46 1.41 1.06 1.39 1.40 1.37 1.03 0.41
Total Revenue		 1.31 1.68 1.28 1.46 1.41 1.06 1.39 1.40 1.37 1.03 0.41
Operating Revenue		 1.31 1.68 1.28 1.46 1.41 1.06 1.39 1.40 1.37 1.03 0.41
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 5.17 4.98 4.98 5.26 5.31 4.60 2.93 5.88 7.11 8.15 9.47
Selling, General & Admin Expense		 2.38 2.21 2.20 2.40 3.13 2.84 1.68 3.44 4.17 5.28 5.20
Research & Development Expense		 2.79 2.76 2.77 2.86 2.19 1.76 1.25 2.44 2.94 2.87 4.27
Total Other Income / (Expense), net		 0.05 0.04 0.76 0.93 -0.00 -14 6.69 0.06 0.03 0.17 0.05
Interest Expense		 0.06 0.03 0.03 0.06 0.06 0.55 0.00 0.00 - 0.02 0.01
Interest & Investment Income		 0.11 0.07 0.07 0.08 0.05 0.00 0.03 0.06 0.03 0.19 0.06
Other Income / (Expense), net		 - 0.00 0.72 0.91 - -13 6.66 0.00 - 0.00 0.00
Other Gains / (Losses), net		 -0.04 - - - - - - - - - 0.05
Basic Earnings per Share		 ($1.21) ($0.75) ($0.45) ($0.37) ($0.59) ($29.86) $0.62 ($0.04) $0.92 ($1.05) ($1.31)
Weighted Average Basic Shares Outstanding		 3.14M 4.32M 6.50M 7.86M 6.64M 582.67K 1.94M 107.43M 77.80M 6.65M 6.90M
Diluted Earnings per Share		 ($1.21) ($0.75) ($0.71) ($0.37) ($0.59) ($29.86) ($0.16) ($0.04) $0.95 ($1.05) ($1.31)
Weighted Average Diluted Shares Outstanding		 3.14M 4.32M 10.74M 7.86M 7.70M 582.67K 8.37M 107.43M 77.80M 6.65M 6.90M
Weighted Average Basic & Diluted Shares Outstanding		 4.28M - 5.90M 5.90M 17.00M 32.72M 99.26M 137.43M 171.55M 6.88M 7.59M

Annual Cash Flow Statements for Plus Therapeutics

This table details how cash moves in and out of Plus Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.28 -1.78 -2.69 -4.92 12 -9.25 10 -0.28 -9.57 -8.48 8.68
Net Cash From Operating Activities		 -20 -20 -18 -12 -5.91 -8.43 -10 -13 -13 -11 -21
Net Cash From Continuing Operating Activities		 -20 -20 -18 -12 -5.91 -8.43 -10 -13 -13 -11 -21
Net Income / (Loss) Continuing Operations		 -19 -22 -23 -13 -11 -8.24 -13 -20 -13 -13 -22
Consolidated Net Income / (Loss)		 -19 -22 -23 -13 -11 -8.24 -13 -20 -13 -13 -22
Depreciation Expense		 1.09 1.18 2.15 2.00 0.90 0.37 0.40 0.62 0.63 0.87 0.45
Amortization Expense		 0.98 0.95 0.71 0.58 0.55 0.58 0.57 0.39 0.19 -0.11 -0.01
Non-Cash Adjustments To Reconcile Net Income		 -5.10 1.40 2.74 -0.89 4.47 -1.26 0.92 0.70 0.76 -2.13 7.47
Changes in Operating Assets and Liabilities, net		 1.30 -1.09 -1.04 -1.03 -0.94 0.12 1.24 5.60 -1.12 3.79 -6.29
Net Cash From Investing Activities		 -0.61 0.06 -1.38 -0.13 5.57 -0.49 -0.08 -0.76 -0.16 -4.11 -0.85
Net Cash From Continuing Investing Activities		 -0.61 0.06 -1.38 -0.13 5.57 -0.49 -0.08 -0.76 -0.16 -4.11 -0.85
Purchase of Property, Plant & Equipment		 -0.61 -0.07 -1.50 -0.13 -0.07 -0.09 -0.14 -0.51 -0.16 -0.15 -0.07
Acquisitions		 -0.01 - - - 0.00 -0.40 - - 0.00 -0.55 0.00
Purchase of Investments		 - - - - - - - - 0.00 -16 -9.35
Sale of Property, Plant & Equipment		 0.01 0.13 0.11 - - 0.00 0.06 - - 0.00 0.03
Sale and/or Maturity of Investments		 - - - - - - - - 0.00 12 8.54
Other Investing Activities, net		 - 0.00 - - - - 0.00 -0.25 0.00 0.00 0.00
Net Cash From Financing Activities		 21 18 17 7.17 13 -0.32 20 13 3.45 6.19 30
Net Cash From Continuing Financing Activities		 21 18 17 7.17 13 -0.32 20 13 3.45 6.19 30
Repayment of Debt		 -27 0.00 -4.72 0.00 -3.69 -5.31 -0.27 -1.61 -1.61 -4.00 -9.25
Repurchase of Common Equity		 -2.37 -2.08 -2.08 - 0.00 - 0.00 -0.77 -0.47 -0.37 -0.23
Issuance of Debt		 18 - - - - - - - 0.00 3.29 4.49
Issuance of Common Equity		 29 21 24 0.00 16 4.01 19 16 0.00 0.00 23
Other Financing Activities, net		 3.37 -1.77 0.00 7.17 0.36 0.98 2.01 - 5.53 7.27 13
Cash Interest Paid		 1.99 1.62 1.36 1.33 1.19 0.57 0.39 0.33 0.22 0.03 0.00

Quarterly Cash Flow Statements for Plus Therapeutics

This table details how cash moves in and out of Plus Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -2.45 -5.65 2.01 -3.69 -1.15 9.79 -7.63 11 -4.53 -5.74 -0.66
Net Cash From Operating Activities		 -1.88 -4.51 -1.15 -3.68 -1.21 -6.17 -5.80 -2.55 -6.26 -6.24 -7.13
Net Cash From Continuing Operating Activities		 -1.88 -4.51 -1.15 -3.68 -1.21 -6.17 -5.80 -2.55 -6.26 -6.24 -7.13
Net Income / (Loss) Continuing Operations		 -3.81 -3.26 -2.94 -2.87 -3.90 -17 5.15 -4.42 -5.71 -6.95 -9.01
Consolidated Net Income / (Loss)		 -3.81 -3.26 -2.94 -2.87 -3.90 -17 5.15 -4.42 -5.71 -6.95 -9.01
Depreciation Expense		 0.15 0.16 0.17 0.20 0.35 0.15 0.08 0.08 0.15 0.10 0.14
Amortization Expense		 -0.06 0.02 -0.02 -0.05 -0.06 0.04 -0.02 0.00 0.01 -0.01 0.02
Non-Cash Adjustments To Reconcile Net Income		 0.35 0.18 -0.97 -0.80 -0.54 13 -7.52 0.99 0.91 0.01 0.42
Changes in Operating Assets and Liabilities, net		 1.49 -1.60 2.61 -0.16 2.94 -2.01 -3.48 0.81 -1.61 0.61 1.29
Net Cash From Investing Activities		 -0.04 -0.36 -3.80 -0.01 0.06 3.56 -4.63 1.30 -1.08 -8.53 5.37
Net Cash From Continuing Investing Activities		 -0.04 -0.36 -3.80 -0.01 0.06 3.56 -4.63 1.30 -1.08 -8.53 5.37
Purchase of Property, Plant & Equipment		 -0.04 -0.04 -0.08 -0.01 -0.01 -0.00 -0.01 -0.03 -0.03 -0.82 -0.50
Purchase of Investments		 - - - -3.65 -8.45 0.00 - -3.31 1.72 -9.70 -4.35
Sale and/or Maturity of Investments		 - -0.32 0.32 3.65 8.52 3.53 3.13 4.64 -2.77 1.99 10
Net Cash From Financing Activities		 -0.53 -0.78 6.96 - - 12 2.80 12 2.80 9.04 1.11
Net Cash From Continuing Financing Activities		 -0.53 -0.78 6.96 - - 12 2.80 12 2.80 9.04 1.11
Repayment of Debt		 -0.40 -0.40 -3.59 - - -7.00 - -2.25 - -1.10 -0.67
Other Financing Activities, net		 0.35 0.00 7.31 -0.05 - 16 15 -2.25 -0.95 10 1.78

Annual Balance Sheets for Plus Therapeutics

This table presents Plus Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 38 35 32 24 23 12 22 24 11 6.63 16
Total Current Assets		 21 19 15 9.65 20 9.18 20 22 9.83 5.26 15
Cash & Equivalents		 14 13 9.55 5.26 18 8.35 18 18 8.55 0.08 4.26
Restricted Cash		 0.00 0.35 0.68 0.04 0.04 - - - - 0.00 4.50
Short-Term Investments		 - - - - - - - - 0.00 3.53 4.36
Other Current Assets		 1.56 0.87 1.31 0.79 0.96 0.83 1.32 3.70 1.28 1.65 2.06
Plant, Property, & Equipment, net		 1.63 1.16 3.05 2.30 2.18 1.82 1.48 1.32 0.91 0.45 0.26
Total Noncurrent Assets		 15 15 14 12 1.23 1.11 0.78 0.73 0.65 0.93 0.90
Goodwill		 3.92 3.92 3.92 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.37
Intangible Assets		 9.03 8.45 7.21 - 0.00 0.09 0.05 0.09 0.04 0.47 0.33
Other Noncurrent Operating Assets		 1.52 2.34 2.57 0.04 0.85 0.65 0.36 0.26 0.23 0.09 0.19
Total Liabilities & Shareholders' Equity		 38 35 32 24 23 12 22 24 11 6.63 16
Total Liabilities		 25 24 19 19 22 9.07 11 17 13 16 12
Total Current Liabilities		 8.44 13 18 18 14 8.54 5.87 12 11 16 12
Short-Term Debt		 0.00 6.63 14 14 11 6.34 1.61 1.61 3.98 3.29 0.75
Accounts Payable		 6.69 5.87 4.79 2.78 3.28 2.08 4.15 10 6.63 11 5.92
Current Deferred Revenue		 - - - - - - - - 0.00 0.93 0.93
Other Current Liabilities		 1.75 - - - 0.15 0.12 0.11 0.11 0.12 0.04 4.72
Total Noncurrent Liabilities		 17 11 0.20 1.21 7.58 0.54 5.28 5.57 2.01 0.03 0.02
Other Noncurrent Operating Liabilities		 - - - 0.96 7.58 0.54 0.27 1.78 2.01 0.03 0.02
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 12 11 13 5.23 1.16 3.03 11 6.45 -1.35 -8.95 4.00
Total Preferred & Common Equity		 12 11 13 5.23 1.16 3.03 11 6.45 -1.35 -8.95 4.00
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 12 11 13 5.23 1.16 3.03 11 6.45 -1.35 -8.95 4.00
Common Stock		 368 389 413 418 426 437 458 474 479 485 520
Retained Earnings		 -357 -379 -402 -414 -425 -434 -447 -467 -481 -493 -516
Treasury Stock		 - - - - - - - 0.00 -0.13 -0.50 -0.50

Quarterly Balance Sheets for Plus Therapeutics

This table presents Plus Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 13 5.62 11 6.98 12 10 19 20 14
Total Current Assets		 12 4.21 9.38 5.36 11 9.21 18 18 12
Cash & Equivalents		 11 2.90 4.91 1.22 9.87 2.23 13 3.02 2.37
Restricted Cash		 - - - - - - - 0.00 0.00
Short-Term Investments		 - 0.32 3.52 3.57 0.00 4.65 3.31 12 6.22
Other Current Assets		 0.58 0.99 0.95 0.58 1.00 2.34 0.99 2.91 3.18
Plant, Property, & Equipment, net		 1.01 0.80 0.73 0.59 0.32 0.29 0.27 1.01 1.41
Total Noncurrent Assets		 0.69 0.61 1.10 1.02 0.86 0.85 0.81 0.88 0.85
Goodwill		 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.37
Intangible Assets		 0.05 0.03 0.56 0.51 0.44 0.40 0.37 0.30 0.27
Other Noncurrent Operating Assets		 0.26 0.20 0.17 0.14 0.06 0.07 0.07 0.20 0.21
Total Liabilities & Shareholders' Equity		 13 5.62 11 6.98 12 10 19 20 14
Total Liabilities		 11 10 19 12 36 7.32 14 7.96 8.57
Total Current Liabilities		 11 10 19 12 11 7.32 14 7.96 8.57
Short-Term Debt		 4.35 3.59 3.29 3.29 0.00 0.00 0.00 0.67 0.00
Accounts Payable		 6.07 6.45 6.95 7.91 9.22 6.36 12 6.16 7.55
Current Deferred Revenue		 - 0.25 2.30 0.84 1.30 0.93 1.97 0.93 0.93
Other Current Liabilities		 0.12 0.12 6.25 0.07 0.04 0.03 0.02 0.20 0.09
Total Noncurrent Liabilities		 0.12 0.06 0.05 0.04 25 0.00 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 0.12 0.06 0.05 0.04 25 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 2.62 -4.84 -7.63 -5.17 -24 3.03 5.05 12 5.46
Total Preferred & Common Equity		 2.62 -4.84 -7.63 -5.17 -24 3.03 5.05 12 5.46
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 2.62 -4.84 -7.63 -5.17 -24 3.03 5.05 12 5.46
Common Stock		 479 479 480 485 488 509 516 535 538
Retained Earnings		 -477 -484 -487 -490 -511 -506 -510 -523 -532
Treasury Stock		 - -0.50 -0.50 -0.50 -0.50 -0.50 -0.50 -0.50 -0.50

Annual Metrics And Ratios for Plus Therapeutics

This table displays calculated financial ratios and metrics derived from Plus Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 158,458,195.00 20,500,553.00 35,119,410.00 13,201,410.00 3,770,588.00 4,779,584.00 15,360,025.00 33,601,373.00 4,522,656.00 5,896,333.00 137,429,055.00
DEI Adjusted Shares Outstanding		 1,409.00 2,733.00 4,683.00 17,602.00 251,373.00 318,639.00 1,024,002.00 2,240,092.00 4,522,656.00 235,853.00 5,497,162.00
DEI Earnings Per Adjusted Shares Outstanding		 -13,772.18 -8,066.59 -5,693.57 -859.05 -45.51 -25.86 -13.08 -9.05 -2.94 -55.03 -4.07
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -2.32% -3.76% -42.25% -100.00% 0.00% 0.00% 0.00% 0.00% 2,093.30% 18.54% -10.49%
EBITDA Growth		 57.93% -32.93% -2.74% 77.84% 43.98% -181.95% -84.81% -62.35% 33.15% 1.54% -74.79%
EBIT Growth		 54.20% -28.84% -6.15% 68.41% 43.99% -96.45% -73.80% -57.87% 32.42% 1.87% -67.95%
NOPAT Growth		 52.87% -28.92% -4.96% 57.64% 58.26% -162.07% -30.34% -57.80% 32.42% -10.31% -4.10%
Net Income Growth		 49.84% -17.62% -2.90% 44.31% 13.83% 24.30% -62.59% -51.32% 34.32% 2.54% -72.49%
EPS Growth		 49.84% 38.16% -2.90% 44.31% 90.49% 77.51% 40.32% -51.32% 63.39% 44.81% 87.61%
Operating Cash Flow Growth		 32.52% 4.57% 7.19% 33.94% 50.68% -42.80% -21.89% -26.19% 0.93% 17.87% -96.84%
Free Cash Flow Firm Growth		 -45.43% 24.10% 0.94% 167.43% -72.10% -559.18% 48.30% -25.02% -14.30% 28.21% -66.97%
Invested Capital Growth		 200.19% 10.66% 4.37% -99.75% -13,202.44% 118.99% -193.24% -560.46% 5.65% -56.31% 9.66%
Revenue Q/Q Growth		 -15.88% -1.90% -23.02% -100.00% 100.00% 0.00% 0.00% 206.85% 30.98% 1.73% -0.86%
EBITDA Q/Q Growth		 17.11% -14.46% 2.55% 49.00% -1,105.00% 15.60% -4.58% -10.27% 11.57% 12.59% -9.38%
EBIT Q/Q Growth		 14.72% -12.87% 2.06% 36.28% -122.18% 14.49% -4.50% -9.03% 11.40% 10.79% -9.16%
NOPAT Q/Q Growth		 12.77% -8.30% -0.20% 27.32% -105.22% -14.08% -4.55% -9.03% 11.40% -0.29% -13.69%
Net Income Q/Q Growth		 13.77% -10.83% 2.71% 13.96% 22.27% -118.59% -4.43% -8.01% 12.19% -0.72% -8.80%
EPS Q/Q Growth		 13.77% -31.96% 2.71% 13.96% 53.06% -100.00% -18.09% -8.01% 9.79% -42.68% -52.63%
Operating Cash Flow Q/Q Growth		 2.08% 1.81% -0.35% 12.66% 37.37% -102.06% 5.51% 2.92% 2.67% 5.97% -32.08%
Free Cash Flow Firm Q/Q Growth		 -37,883.43% 42.07% -2.74% 281.50% -84.00% -2.08% 8.65% 8.77% -0.47% 8.84% -155.46%
Invested Capital Q/Q Growth		 574.86% -0.51% 1.83% -99.69% 7.01% -13.27% -518.94% -99.65% -46.83% -38.88% 27.53%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 34.15% 41.69% 5.43% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -269.57% -372.36% -662.40% 0.00% 0.00% 0.00% 0.00% -8,350.00% -254.49% -211.38% -412.78%
Operating Margin		 -315.96% -423.24% -769.17% 0.00% 0.00% 0.00% 0.00% -8,800.00% -271.14% -252.32% -293.46%
EBIT Margin		 -312.40% -418.23% -768.69% 0.00% 0.00% 0.00% 0.00% -8,800.00% -271.14% -224.45% -421.14%
Profit (Net Income) Margin		 -387.43% -473.50% -843.66% 0.00% 0.00% 0.00% 0.00% -9,051.34% -271.04% -222.84% -429.43%
Tax Burden Percent		 100.00% 100.00% 100.00% 150.26% 199.51% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 124.02% 113.21% 109.75% 128.78% 149.22% 114.71% 107.31% 102.86% 99.96% 99.28% 101.97%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -113.06% -92.23% -90.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -242.53% -337.82% -292.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -463.33% -97.89% -98.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -576.38% -190.12% -189.16% -138.64% -341.02% -393.27% -193.25% -234.65% -522.50% 252.07% 903.94%
Cash Return on Invested Capital (CROIC)		 -213.10% -102.35% -94.45% 124.39% 0.00% -1,284.39% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -39.56% -53.86% -62.42% 0.00% 0.00% 0.00% 0.00% -85.99% -75.57% -145.08% -191.25%
Return on Assets (ROA)		 -49.06% -60.98% -68.51% 0.00% 0.00% 0.00% 0.00% -88.44% -75.54% -144.03% -195.02%
Return on Common Equity (ROCE)		 -576.38% -190.12% -189.16% -138.64% -341.02% -393.27% -193.25% -234.65% -522.50% 252.07% 903.94%
Return on Equity Simple (ROE_SIMPLE)		 -153.56% -200.67% -174.51% -241.80% -938.53% -271.89% -123.65% -314.58% 987.83% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -14 -14 -6.13 -2.56 -6.71 -8.74 -14 -9.32 -10 -11
NOPAT Margin		 -221.17% -296.27% -538.42% 0.00% 0.00% 0.00% 0.00% -6,160.00% -189.80% -176.62% -205.42%
Net Nonoperating Expense Percent (NNEP)		 129.48% 245.59% 202.02% -728.36% -142.15% -35.87% -67.47% -52.84% -46.13% -110.04% -184.22%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -354.82% 181.84% -225.63%
Cost of Revenue to Revenue		 65.85% 58.31% 94.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 201.84% 183.91% 282.41% 0.00% 0.00% 0.00% 0.00% 4,570.54% 173.91% 170.66% 232.73%
R&D to Revenue		 251.74% 203.46% 496.99% 0.00% 0.00% 0.00% 0.00% 4,329.46% 197.23% 181.66% 160.73%
Operating Expenses to Revenue		 350.10% 464.93% 774.60% 0.00% 0.00% 0.00% 0.00% 8,900.00% 371.14% 352.32% 393.46%
Earnings before Interest and Taxes (EBIT)		 -15 -19 -21 -6.53 -3.66 -7.18 -12 -20 -13 -13 -22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -17 -18 -3.95 -2.21 -6.23 -12 -19 -13 -12 -22
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.40 2.82 0.81 0.73 7.80 3.19 1.49 1.65 0.00 0.00 17.62
Price to Tangible Book Value (P/TBV)		 0.00 0.00 5.66 0.79 11.48 3.75 1.55 1.78 0.00 0.00 21.39
Price to Revenue (P/Rev)		 6.06 6.65 3.94 0.00 0.00 0.00 0.00 47.55 1.61 1.16 13.51
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.23 2.27 0.85 310.47 0.00 7.49 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 6.54 7.66 5.20 0.00 0.00 0.00 0.00 0.00 0.68 1.11 11.13
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 1.25 0.88 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.37 1.61 1.05 2.72 9.53 2.09 0.61 0.84 -2.95 -0.37 0.19
Long-Term Debt to Equity		 1.37 1.00 0.00 0.00 0.00 0.00 0.46 0.59 0.00 0.00 0.00
Financial Leverage		 1.91 0.29 0.34 -0.10 -1.83 -2.04 -1.00 -1.42 -3.39 0.48 2.56
Leverage Ratio		 11.75 3.12 2.76 3.05 7.40 8.43 2.46 2.65 6.92 -1.75 -4.64
Compound Leverage Factor		 14.57 3.53 3.03 3.93 11.04 9.67 2.64 2.73 6.91 -1.74 -4.73
Debt to Total Capital		 57.75% 61.62% 51.17% 73.10% 90.51% 67.64% 37.90% 45.56% 151.29% -58.19% 15.80%
Short-Term Debt to Total Capital		 0.00% 23.16% 51.17% 73.10% 90.51% 67.64% 9.22% 13.58% 151.29% -58.19% 15.80%
Long-Term Debt to Total Capital		 57.75% 38.46% 0.00% 0.00% 0.00% 0.00% 28.68% 31.98% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 42.25% 38.38% 48.83% 26.90% 9.49% 32.36% 62.10% 54.44% -51.29% 158.19% 84.20%
Debt to EBITDA		 -1.28 -1.02 -0.76 -3.60 -5.00 -1.02 -0.57 -0.29 -0.32 -0.27 -0.03
Net Debt to EBITDA		 -0.18 -0.27 -0.19 -2.26 2.95 0.32 1.02 0.68 0.37 0.03 0.57
Long-Term Debt to EBITDA		 -1.28 -0.63 0.00 0.00 0.00 0.00 -0.43 -0.20 0.00 0.00 0.00
Debt to NOPAT		 -1.56 -1.28 -0.94 -2.32 -4.32 -0.94 -0.76 -0.39 -0.43 -0.32 -0.07
Net Debt to NOPAT		 -0.22 -0.34 -0.23 -1.45 2.55 0.30 1.35 0.92 0.49 0.03 1.15
Long-Term Debt to NOPAT		 -1.56 -0.80 0.00 0.00 0.00 0.00 -0.57 -0.27 0.00 0.00 0.00
Altman Z-Score		 -13.36 -16.05 -19.66 -25.35 -25.63 -51.39 -28.71 -29.25 -62.22 -111.38 -44.72
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.52 1.50 0.81 0.55 1.37 1.07 3.36 1.84 0.92 0.34 1.23
Quick Ratio		 1.82 1.10 0.53 0.31 1.29 0.98 3.13 1.53 0.80 0.23 0.70
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -20 -15 -15 10 2.85 -13 -6.77 -8.47 -9.68 -6.95 -12
Operating Cash Flow to CapEx		 -3,411.33% 0.00% -1,310.77% -9,003.76% -8,814.93% -9,068.82% -12,536.59% -2,548.53% -8,031.88% -7,228.77% -56,148.65%
Free Cash Flow to Firm to Interest Expense		 -5.54 -5.91 -7.40 5.32 1.54 -11.83 -7.27 -11.91 -24.51 -38.82 -21.17
Operating Cash Flow to Interest Expense		 -5.62 -7.54 -8.85 -6.23 -3.18 -7.62 -11.03 -18.24 -32.53 -58.96 -37.91
Operating Cash Flow Less CapEx to Interest Expense		 -5.79 -7.51 -9.52 -6.30 -3.22 -7.70 -11.12 -18.96 -32.94 -59.78 -37.98
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.13 0.13 0.08 0.00 0.00 0.00 0.00 0.01 0.28 0.65 0.45
Accounts Receivable Turnover		 4.22 4.06 3.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.70 0.68 0.74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 3.01 3.34 1.28 0.00 0.00 0.00 0.00 0.16 4.41 8.60 14.79
Accounts Payable Turnover		 0.52 0.43 0.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 86.57 89.92 94.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 522.81 539.30 495.76 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 700.73 844.21 765.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -91.35 -214.99 -175.27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 14 16 16 0.04 -5.37 1.02 -0.95 -6.28 -5.93 -9.26 -8.37
Invested Capital Turnover		 0.51 0.31 0.17 0.00 0.00 0.00 0.00 -0.06 -0.80 -0.77 -0.59
Increase / (Decrease) in Invested Capital		 9.47 1.51 0.69 -16 -5.41 6.39 -1.97 -5.33 0.36 -3.34 0.90
Enterprise Value (EV)		 32 36 14 13 2.52 7.64 4.34 -2.07 3.34 6.47 58
Market Capitalization		 29 31 11 3.83 9.05 9.65 16 11 7.92 6.78 70
Book Value per Share		 $0.08 $0.54 $0.37 $0.40 $0.31 $0.63 $0.71 $0.19 ($0.30) ($1.52) $0.03
Tangible Book Value per Share		 $0.00 ($0.07) $0.05 $0.37 $0.21 $0.54 $0.68 $0.18 ($0.39) ($1.66) $0.02
Total Capital		 29 29 27 19 12 9.37 17 12 2.63 -5.66 4.75
Total Debt		 17 18 14 14 11 6.34 6.61 5.39 3.98 3.29 0.75
Total Long-Term Debt		 17 11 0.00 0.00 0.00 0.00 5.01 3.79 0.00 0.00 0.00
Net Debt		 2.34 4.73 3.40 8.90 -6.53 -2.01 -12 -13 -4.58 -0.31 -12
Capital Expenditures (CapEx)		 0.60 -0.06 1.38 0.13 0.07 0.09 0.08 0.51 0.16 0.15 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.53 -0.04 -0.15 0.99 -1.19 -1.38 -2.94 -6.55 -5.47 -11 -9.51
Debt-free Net Working Capital (DFNWC)		 13 13 10 6.29 16 6.97 15 12 3.08 -7.00 3.61
Net Working Capital (NWC)		 13 6.25 -3.55 -7.91 5.34 0.64 14 9.97 -0.89 -10 2.86
Net Nonoperating Expense (NNE)		 8.04 8.25 8.21 6.50 8.33 1.53 4.65 6.48 3.99 2.69 12
Net Nonoperating Obligations (NNO)		 1.99 4.73 3.40 -5.18 -6.53 -2.01 -12 -13 -4.58 -0.31 -12
Total Depreciation and Amortization (D&A)		 2.07 2.14 2.86 2.58 1.45 0.95 0.97 1.01 0.82 0.76 0.44
Debt-free, Cash-free Net Working Capital to Revenue		 -31.67% -0.75% -5.62% 0.00% 0.00% 0.00% 0.00% -2,922.77% -111.36% -182.11% -182.39%
Debt-free Net Working Capital to Revenue		 264.70% 276.52% 374.64% 0.00% 0.00% 0.00% 0.00% 5,166.52% 62.75% -120.19% 69.17%
Net Working Capital to Revenue		 264.70% 134.15% -132.02% 0.00% 0.00% 0.00% 0.00% 4,448.66% -18.18% -176.72% 54.79%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($15,750.00) ($9,600.00) ($6,150.00) ($1,305.00) ($124.05) ($27.90) ($16.65) ($11.55) ($4.24) ($48.75) ($7.25)
Adjusted Weighted Average Basic Shares Outstanding		 1.74K 2.93K 7.98K 21.77K 258.71K 1.41M 1.48M 1.75M 3.14M 265.61K 3.11M
Adjusted Diluted Earnings per Share		 ($15,750.00) ($9,600.00) ($6,150.00) ($1,305.00) ($124.05) ($27.90) ($16.65) ($11.55) ($4.24) ($58.50) ($7.25)
Adjusted Weighted Average Diluted Shares Outstanding		 1.74K 2.93K 7.98K 21.77K 258.71K 1.41M 1.48M 1.75M 3.14M 308.03K 3.11M
Adjusted Basic & Diluted Earnings per Share		 ($15,750.00) ($9,600.00) ($6,150.00) ($1,305.00) ($124.05) ($27.90) ($16.65) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.25K 2.31K 4.32K 11.59K 92.27K 295.19K 805.95K 2.34M 4.28M 679.99K 6.86M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -14 -14 -6.13 -2.56 -6.71 -8.70 -14 -9.32 -10 -11
Normalized NOPAT Margin		 -221.17% -296.27% -538.42% 0.00% 0.00% 0.00% 0.00% -6,160.00% -189.80% -176.62% -205.42%
Pre Tax Income Margin		 -387.43% -473.50% -843.66% 0.00% 0.00% 0.00% 0.00% -9,051.79% -271.04% -222.84% -429.43%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -4.15 -7.51 -10.09 -3.40 -1.97 -6.49 -13.40 -27.72 -33.72 -73.03 -40.06
NOPAT to Interest Expense		 -2.94 -5.32 -7.07 -3.19 -1.38 -6.06 -9.38 -19.41 -23.61 -57.47 -19.54
EBIT Less CapEx to Interest Expense		 -4.32 -7.49 -10.76 -3.47 -2.01 -6.57 -13.49 -28.44 -34.13 -73.84 -40.13
NOPAT Less CapEx to Interest Expense		 -3.11 -5.30 -7.74 -3.26 -1.42 -6.14 -9.47 -20.12 -24.01 -58.28 -19.61
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 -0.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -13.04% -9.45% -9.16% 0.00% 0.00% 0.00% 0.00% -3.81% -3.56% -2.88% -1.03%

Quarterly Metrics And Ratios for Plus Therapeutics

This table displays calculated financial ratios and metrics derived from Plus Therapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 4,522,656.00 4,276,082.00 4,276,082.00 5,896,333.00 5,896,333.00 16,999,626.00 32,717,054.00 99,264,526.00 137,429,055.00 171,550,698.00 6,883,106.00
DEI Adjusted Shares Outstanding		 4,522,656.00 4,276,082.00 4,276,082.00 5,896,333.00 235,853.00 679,985.00 32,717,054.00 99,264,526.00 5,497,162.00 6,862,028.00 6,883,106.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.84 -0.76 -0.69 -0.49 -16.55 -25.59 0.16 -0.04 -1.04 -1.01 -1.31
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 769.54% 231.42% -31.01% 17.42% 7.54% -36.85% 8.68% -4.05% -3.19% -2.93% -70.43%
EBITDA Growth		 30.30% 30.48% -131.97% 9.30% 3.99% -433.19% 283.00% -60.60% -54.64% 57.83% -273.02%
EBIT Growth		 30.76% 30.14% -100.00% 11.01% -1.09% -410.88% 271.95% -54.93% -47.23% 57.76% -276.76%
NOPAT Growth		 30.76% 30.14% -148.12% -16.86% -1.09% -7.18% 40.57% -17.98% -47.23% -101.33% -312.22%
Net Income Growth		 32.66% 32.13% -98.38% 10.72% -2.44% -433.61% 275.20% -53.90% -46.37% 60.08% -274.84%
EPS Growth		 62.54% 63.77% -20.34% 63.00% 51.24% -433.61% 98.59% 89.19% 261.02% 60.08% -718.75%
Operating Cash Flow Growth		 15.80% 22.10% 58.60% -53.40% 35.62% -36.76% -404.17% 30.76% -416.68% -1.07% -23.01%
Free Cash Flow Firm Growth		 -313.74% -300.08% 6,761.96% 98.17% 119.87% 1,039.14% -257.16% 6,975.89% -909.62% -235.55% 32.50%
Invested Capital Growth		 5.65% 10.40% -262.32% -65.26% -56.31% -649.45% 69.89% -73.12% 9.66% 92.58% 18.75%
Revenue Q/Q Growth		 5.89% 27.72% -23.73% 13.84% -3.02% -25.00% 31.26% 0.50% -2.15% -24.80% -60.02%
EBITDA Q/Q Growth		 -24.52% 16.90% 9.50% 3.14% -31.81% -361.47% 131.00% -185.00% -26.92% -25.85% -26.58%
EBIT Q/Q Growth		 -18.67% 14.49% 9.67% 2.92% -34.81% -332.15% 130.40% -187.47% -28.11% -23.98% -27.22%
NOPAT Q/Q Growth		 -18.67% 14.49% -12.06% -2.76% -2.66% 9.33% 37.86% -103.99% -28.11% -23.98% -27.22%
Net Income Q/Q Growth		 -18.36% 14.41% 9.84% 2.24% -35.80% -345.84% 129.60% -185.87% -29.17% -21.58% -29.66%
EPS Q/Q Growth		 -21.00% 38.02% 5.33% 47.89% -59.46% -345.84% 99.16% -300.00% 2,475.00% -21.58% -24.76%
Operating Cash Flow Q/Q Growth		 21.59% -139.93% 74.52% -220.00% 67.09% -409.66% 6.06% 56.05% -145.57% 0.30% -14.33%
Free Cash Flow Firm Q/Q Growth		 -120.51% 7.44% 335.34% -100.38% 2,499.21% 4,275.91% -139.38% 116.63% -382.50% -632.65% 80.39%
Invested Capital Q/Q Growth		 -46.83% 24.55% -185.57% 47.76% -38.88% -261.74% 88.53% -200.31% 27.53% 70.29% -25.66%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -286.60% -186.46% -221.27% -188.26% -255.88% -1,574.41% 372.59% -315.10% -408.71% -683.95% -2,165.45%
Operating Margin		 -293.83% -196.72% -289.05% -260.92% -276.20% -333.90% -110.65% -320.83% -420.04% -692.51% -2,203.65%
EBIT Margin		 -293.83% -196.72% -232.99% -198.70% -276.20% -1,591.50% 368.63% -320.83% -420.04% -692.51% -2,203.65%
Profit (Net Income) Margin		 -290.18% -194.45% -229.87% -197.39% -276.42% -1,643.15% 370.58% -316.61% -417.92% -675.68% -2,191.24%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 98.76% 98.85% 98.66% 99.34% 100.08% 103.25% 100.53% 98.68% 99.49% 97.57% 99.44%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -522.50% 1,089.50% 533.15% 1,009.80% 252.07% 190.45% 828.88% 34,293.33% 903.94% 204.30% -614.05%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -81.89% -112.60% -101.03% -112.32% -178.53% -937.42% 181.80% -131.54% -190.76% -224.48% -759.80%
Return on Assets (ROA)		 -80.88% -111.30% -99.68% -111.58% -178.66% -967.84% 182.76% -129.81% -189.79% -219.03% -755.52%
Return on Common Equity (ROCE)		 -522.50% 1,089.50% 533.15% 1,009.80% 252.07% 190.45% 828.88% 34,293.33% 903.94% 204.30% -614.05%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 243.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.70 -2.31 -2.59 -2.66 -2.73 -2.48 -1.54 -3.14 -4.02 -4.98 -6.34
NOPAT Margin		 -205.68% -137.70% -202.34% -182.64% -193.34% -233.73% -110.65% -224.58% -294.03% -484.76% -1,542.55%
Net Nonoperating Expense Percent (NNEP)		 -12.82% -26.07% -6.22% -5.27% -47.96% -314.19% 111.28% -14.21% -26.72% -16.14% -34.48%
Return On Investment Capital (ROIC_SIMPLE)		 -102.76% 185.19% 59.73% 141.30% 48.26% 10.47% -50.69% -62.08% -84.69% -39.46% -116.05%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 181.04% 131.96% 172.24% 164.63% 221.39% 268.08% 121.01% 246.46% 304.90% 513.81% 1,265.94%
R&D to Revenue		 212.80% 164.76% 216.81% 196.29% 154.82% 165.82% 89.64% 174.37% 215.14% 278.70% 1,037.71%
Operating Expenses to Revenue		 393.83% 296.72% 389.05% 360.92% 376.20% 433.90% 210.65% 420.83% 520.04% 792.51% 2,303.65%
Earnings before Interest and Taxes (EBIT)		 -3.86 -3.30 -2.98 -2.89 -3.90 -17 5.12 -4.48 -5.74 -7.12 -9.06
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.76 -3.13 -2.83 -2.74 -3.61 -17 5.18 -4.40 -5.59 -7.03 -8.90
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 3.75 13.43 17.62 2.33 5.51
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 5.03 15.75 21.39 2.47 6.23
Price to Revenue (P/Rev)		 1.61 1.27 1.14 1.50 1.16 3.10 2.14 12.91 13.51 5.38 7.16
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.68 1.33 0.21 1.24 1.11 1.21 0.85 9.75 11.13 2.60 5.11
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.34 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -2.95 -0.74 -0.43 -0.64 -0.37 0.00 0.00 0.00 0.19 0.06 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -3.39 3.38 2.28 3.20 0.48 0.33 2.62 150.81 2.56 2.08 -1.82
Leverage Ratio		 6.92 -9.84 -5.12 -7.94 -1.75 -0.62 -4.70 -213.73 -4.64 -2.74 2.87
Compound Leverage Factor		 6.83 -9.72 -5.05 -7.89 -1.75 -0.64 -4.72 -210.92 -4.61 -2.67 2.85
Debt to Total Capital		 151.29% -287.89% -75.98% -174.92% -58.19% 0.00% 0.00% 0.00% 15.80% 5.28% 0.00%
Short-Term Debt to Total Capital		 151.29% -287.89% -75.98% -174.92% -58.19% 0.00% 0.00% 0.00% 15.80% 5.28% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -51.29% 387.89% 175.98% 274.92% 158.19% 100.00% 100.00% 100.00% 84.20% 94.72% 100.00%
Debt to EBITDA		 -0.32 -0.32 -0.24 -0.23 -0.27 0.00 0.00 0.00 -0.03 -0.06 0.00
Net Debt to EBITDA		 0.37 -0.03 0.38 0.11 0.03 0.00 0.00 0.00 0.57 1.22 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.43 -0.43 -0.33 -0.32 -0.32 0.00 0.00 0.00 -0.07 -0.05 0.00
Net Debt to NOPAT		 0.49 -0.04 0.52 0.15 0.03 0.00 0.00 0.00 1.15 1.09 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -59.48 -122.22 -61.97 -99.51 -106.82 -63.21 -65.11 -35.52 -41.44 -34.96 -52.52
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.92 0.41 0.50 0.44 0.34 1.03 1.26 1.29 1.23 2.27 1.37
Quick Ratio		 0.80 0.31 0.45 0.40 0.23 0.93 0.94 1.22 0.70 1.90 1.00
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.06 -2.83 6.66 -0.03 0.61 27 -10 1.74 -4.91 -36 -7.06
Operating Cash Flow to CapEx		 -4,478.57% -11,282.50% -1,419.75% -26,285.71% -11,009.09% 0.00% -82,828.57% -9,437.04% -20,856.67% -762.59% -1,429.26%
Free Cash Flow to Firm to Interest Expense		 -49.28 -83.19 246.52 -0.41 10.65 48.47 0.00 0.00 0.00 -2,117.96 -1,412.18
Operating Cash Flow to Interest Expense		 -30.34 -132.74 -42.59 -60.33 -21.25 -11.26 0.00 0.00 0.00 -366.94 -1,426.40
Operating Cash Flow Less CapEx to Interest Expense		 -31.02 -133.91 -45.59 -60.56 -21.44 -11.21 0.00 0.00 0.00 -415.06 -1,526.20
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.28 0.57 0.43 0.57 0.65 0.59 0.49 0.41 0.45 0.32 0.34
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 4.41 5.86 5.88 7.16 8.60 9.26 10.42 12.17 14.79 7.75 4.95
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -5.93 -4.47 -13 -6.67 -9.26 -34 -3.85 -12 -8.37 -2.49 -3.12
Invested Capital Turnover		 -0.80 -1.29 -0.68 -1.07 -0.77 -0.27 -0.64 -0.58 -0.59 -0.29 -1.21
Increase / (Decrease) in Invested Capital		 0.36 0.52 -9.24 -2.63 -3.34 -29 8.92 -4.88 0.90 31 0.72
Enterprise Value (EV)		 3.34 8.08 1.14 7.11 6.47 6.28 4.50 51 58 13 21
Market Capitalization		 7.92 7.72 6.29 8.61 6.78 16 11 68 70 28 30
Book Value per Share		 ($0.30) ($1.13) ($1.17) ($0.88) ($1.52) ($4.01) $0.09 $0.05 $0.03 $0.07 $0.79
Tangible Book Value per Share		 ($0.39) ($1.23) ($1.32) ($1.03) ($1.66) ($4.15) $0.07 $0.04 $0.02 $0.07 $0.70
Total Capital		 2.63 -1.25 -4.33 -1.88 -5.66 -24 3.03 5.05 4.75 13 5.46
Total Debt		 3.98 3.59 3.29 3.29 3.29 0.00 0.00 0.00 0.75 0.67 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -4.58 0.37 -5.14 -1.50 -0.31 -9.87 -6.88 -17 -12 -14 -8.59
Capital Expenditures (CapEx)		 0.04 0.04 0.08 0.01 0.01 -0.03 0.01 0.03 0.03 0.82 0.50
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.47 -5.82 -15 -8.24 -11 -9.56 -4.98 -13 -9.51 -4.37 -5.38
Debt-free Net Working Capital (DFNWC)		 3.08 -2.60 -6.12 -3.46 -7.00 0.31 1.90 3.97 3.61 11 3.20
Net Working Capital (NWC)		 -0.89 -6.19 -9.41 -6.75 -10 0.31 1.90 3.97 2.86 10 3.20
Net Nonoperating Expense (NNE)		 1.11 0.95 0.35 0.21 1.17 15 -6.69 1.29 1.69 1.96 2.67
Net Nonoperating Obligations (NNO)		 -4.58 0.37 -5.14 -1.50 -0.31 -9.87 -6.88 -17 -12 -14 -8.59
Total Depreciation and Amortization (D&A)		 0.10 0.17 0.15 0.15 0.29 0.18 0.06 0.08 0.16 0.09 0.16
Debt-free, Cash-free Net Working Capital to Revenue		 -111.36% -95.66% -264.11% -144.00% -182.11% -183.60% -93.68% -240.22% -182.39% -84.41% -128.08%
Debt-free Net Working Capital to Revenue		 62.75% -42.67% -111.00% -60.37% -120.19% 5.94% 35.70% 75.50% 69.17% 207.26% 76.23%
Net Working Capital to Revenue		 -18.18% -101.68% -170.76% -117.87% -176.72% 5.94% 35.70% 75.50% 54.79% 194.38% 76.23%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.21) ($0.75) ($0.45) ($0.37) ($14.75) ($29.75) $0.02 ($0.04) $23.00 ($1.05) ($1.31)
Adjusted Weighted Average Basic Shares Outstanding		 3.14M 4.32M 6.50M 7.86M 265.61K 582.67K 48.39M 107.43M 3.11M 6.65M 6.90M
Adjusted Diluted Earnings per Share		 ($1.21) ($0.75) ($0.71) ($0.37) ($14.75) ($29.75) ($0.01) ($0.04) $23.75 ($1.05) ($1.31)
Adjusted Weighted Average Diluted Shares Outstanding		 3.14M 4.32M 10.74M 7.86M 308.03K 582.67K 209.15M 107.43M 3.11M 6.65M 6.90M
Adjusted Basic & Diluted Earnings per Share		 ($1.21) $0.00 $0.00 $0.00 ($14.75) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.28M 0.00 5.90M 5.90M 679.99K 1.31M 99.26M 137.43M 6.86M 6.88M 7.59M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.70 -2.31 -2.59 -2.66 -2.73 -2.48 -1.08 -3.14 -4.02 -4.98 -6.34
Normalized NOPAT Margin		 -205.68% -137.70% -202.34% -182.64% -193.34% -233.73% -77.45% -224.58% -294.03% -484.76% -1,542.55%
Pre Tax Income Margin		 -290.18% -194.45% -229.87% -197.39% -276.42% -1,643.15% 370.58% -316.61% -417.92% -675.68% -2,191.24%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -62.23 -97.03 -110.37 -47.43 -68.42 -30.76 0.00 0.00 0.00 -418.76 -1,811.40
NOPAT to Interest Expense		 -43.56 -67.92 -95.85 -43.60 -47.89 -4.52 0.00 0.00 0.00 -293.14 -1,267.98
EBIT Less CapEx to Interest Expense		 -62.90 -98.21 -113.37 -47.66 -68.61 -30.71 0.00 0.00 0.00 -466.88 -1,911.20
NOPAT Less CapEx to Interest Expense		 -44.24 -69.10 -98.85 -43.82 -48.09 -4.47 0.00 0.00 0.00 -341.25 -1,367.78
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -3.56% -7.20% -6.75% -6.58% -2.88% 0.00% -0.92% -1.12% -1.03% -13.36% -5.27%

Financials Breakdown Chart

Key Financial Trends

Plus Therapeutics (NASDAQ: PSTV) remains in a financially challenging position. The latest data show declining revenue, widening operating losses and substantial cash burn. Although the company has no short-term debt reported at June 30, 2026, its liquidity has weakened materially since the beginning of the year and it continues to rely on financing and investment sales to support operations.

  • The company reported $8.6 million in cash and short-term investments at June 30, 2026, including $2.4 million of cash and $6.2 million of short-term investments. Total current assets of $11.8 million exceeded current liabilities of $8.6 million, producing a current ratio of approximately 1.4.
  • Reported short-term debt declined from $667,000 in Q1 2026 to zero in Q2 2026. The company also recorded $672,000 of debt repayments during the second quarter.
  • Investment maturities and sales generated $10.2 million of cash in Q2 2026, more than offsetting $4.3 million of investment purchases and helping produce $5.4 million of net investing cash flow.
  • Revenue continues to be reported with no cost of revenue, resulting in a reported 100% gross margin. However, this benefit is not sufficient to offset operating expenses.
  • The company received $1.1 million of net financing cash flow in Q2 2026, including $1.8 million from other financing activities. This provided some support, but financing inflows have varied significantly from quarter to quarter.
  • Property, plant and equipment increased to $1.4 million in Q2 2026 from $1.0 million in Q1, reflecting $499,000 of capital expenditures during the quarter. The investment could support operations, but it also increases cash needs before profitability is achieved.
  • The financial data include several restated periods and inconsistent company names, including “CERENOME, INC.” in some filings, while the requested company is Plus Therapeutics. Share counts and earnings-per-share figures also vary sharply between reported and restated periods, so historical comparisons should be treated cautiously.
  • Revenue fell to $411,000 in Q2 2026 from $1.0 million in Q1 2026 and $1.4 million in Q4 2025. Revenue has generally remained below the $1.7 million reported in Q1 2024, indicating limited and inconsistent commercial scale.
  • Operating expenses rose to $9.5 million in Q2 2026, up from $8.1 million in Q1 and $7.1 million in Q4 2025. Research and development expense increased to $4.3 million, while selling, general and administrative expense reached $5.2 million.
  • The company posted a $9.0 million net loss and a $9.1 million operating loss in Q2 2026. This compares with a $6.9 million net loss and $7.1 million operating loss in Q1, showing that losses are widening as revenue declines.
  • Operating cash flow remained deeply negative at -$7.1 million in Q2 2026, following outflows of $6.2 million in Q1 and $6.3 million in Q4 2025. At the latest quarterly burn rate, the reported cash and short-term investment balance provides limited operating coverage without additional financing, asset sales or expense reductions.
  • Total cash and short-term investments declined from $15.1 million at March 31, 2026 to $8.6 million at June 30, 2026. Total assets fell from $19.9 million to $14.0 million, while shareholders’ equity dropped from $12.0 million to $5.5 million.
  • Retained earnings were approximately -$531.8 million at June 30, 2026, reflecting the company’s long history of cumulative losses. Accounts payable also remained high at $7.6 million, representing most of the company’s current liabilities.
  • The company continues to face potential dilution risk. Weighted-average basic shares increased from roughly 6.6 million in Q1 2026 to 6.9 million in Q2, while prior periods show substantially larger and inconsistent share counts, suggesting that future capital raises could materially affect existing shareholders.

Overall, the latest statements suggest that Plus Therapeutics has some near-term liquidity and reduced reported debt, but these positives are outweighed by declining revenue, persistent operating losses and a cash burn of more than $7 million per quarter. Investors should focus on whether revenue improves, operating expenses decline and the company can secure funding without substantial shareholder dilution.

11/13/26 05:12 PM ETAI Generated. May Contain Errors.

Plus Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Plus Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

In the past 10 years, Plus Therapeutics' net income has ranged from -$22.69 million in 2017 to -$8.24 million in 2020, and is currently -$22.39 million as of their latest financial filing in 2025. See where experts think Plus Therapeutics is headed by visiting Plus Therapeutics' forecast page.

Plus Therapeutics' total operating income in 2025 was -$15.30 million, based on the following breakdown:
  • Total Gross Profit: $5.21 million
  • Total Operating Expenses: $20.51 million

Over the last 10 years, Plus Therapeutics' total revenue changed from $4.84 million in 2015 to $5.21 million in 2025, a change of 7.8%.

In the past 11 quarters, Plus Therapeutics' cash and equivalents has ranged from $1.22 million in Q3 2024 to $13.29 million in Q3 2025, and is currently $2.37 million as of their latest financial filing in Q2 2026.

Plus Therapeutics had total debt of $750 thousand at the end of 2025, a 77.2% decrease from 2024, and a 95.5% decrease since 2015.

Over the last 10 years, Plus Therapeutics' book value per share changed from 0.08 in 2015 to 0.03 in 2025, a change of -62.2%.



Financial statements for NASDAQ:CNSY last updated on 8/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...
Paradigm Press | Sponsoredtc pixel